Journal of Holistic Integrative Pharmacy最新文献_第5页

Study on the factors affecting the competitiveness of biopharmaceutical industry cluster: Evidence from Guangdong and Zhejiang of China 生物制药产业集群竞争力影响因素研究——以广东、浙江为例

Journal of Holistic Integrative Pharmacy

Pub Date : 2025-03-01 DOI: 10.1016/j.jhip.2025.03.004

Qiu Zhang , Mandong Huang , Xiaoxin Huang , Lu Gan , Yiling Li , Huiying Huang

Objective

This study aims to analyze factors affecting the competitiveness of China's biopharmaceutical industry cluster, offering insights for policymakers and stakeholders, while providing Chinese experience and theoretical support for sustainable development of global biopharmaceutical industry clusters.

Methods

Based on relevant data from Guangdong and Zhejiang Provinces in China, the entropy value method was used to evaluate the comprehensive competitiveness of biopharmaceutical industry clusters in Guangdong and Zhejiang provinces respectively, and the principal component regression method was applied to respectively examine factors affecting the competitiveness of biopharmaceutical industry clusters in Guangdong and Zhejiang provinces.

Results

The competitiveness study showed that the comprehensive competitiveness scores of biopharmaceutical industry clusters in Guangdong and Zhejiang both show an upward trend from 2010 to 2020. From 2010 to 2020, the average value of Zhejiang's competitiveness was 0.53 and Guangdong's was 0.41. The influencing factor study showed that the top five factors affecting the competitiveness of biopharmaceutical industry clusters in Guangdong and Zhejiang were the same, namely, the ratio of general public service expenditure to regional GDP, ratio of regional road freight turnover to regional road mileage, proportion of R&D expenditure to total industrial output, ratio of total healthcare expenditure to provincial consumption, and product sales rate.

Conclusion

The results suggested that core factors affecting the competitiveness of China's biopharmaceutical industry cluster center on four aspects: infrastructure, innovation resources, enterprise performance, and market environment. Therefore, the primary strategy is to strengthen infrastructure construction and investment in innovation resources, while balancing enterprise performance with market environment optimization. This study pioneered the research on factors influencing the competitiveness of China's biopharmaceutical industry cluster, providing a new perspective and reference framework for subsequent research in this field.

目的分析影响中国生物制药产业集群竞争力的因素，为政策制定者和利益相关者提供见解，同时为全球生物制药产业集群的可持续发展提供中国经验和理论支持。方法基于广东、浙江两省的相关数据，采用熵值法对广东、浙江两省生物制药产业集群的综合竞争力进行评价，并采用主成分回归法分别对影响广东、浙江两省生物制药产业集群竞争力的因素进行分析。结果竞争力研究表明，2010 - 2020年，广东和浙江生物制药产业集群综合竞争力得分均呈上升趋势。2010 - 2020年，浙江竞争力均值为0.53，广东竞争力均值为0.41。影响因素研究表明，影响广东和浙江生物制药产业集群竞争力的前5个因素是相同的，分别是一般公共服务支出占区域GDP的比例、区域道路货运量占区域道路里程的比例、研发支出占工业总产值的比例、医疗保健总支出占全省消费的比例和产品销售率。结论影响中国生物制药产业集群竞争力的核心因素集中在基础设施、创新资源、企业绩效和市场环境四个方面。因此，加强基础设施建设和创新资源投入，平衡企业绩效和优化市场环境是首要策略。本研究开创了对中国生物制药产业集群竞争力影响因素的研究，为后续研究提供了新的视角和参考框架。

{"title":"Study on the factors affecting the competitiveness of biopharmaceutical industry cluster: Evidence from Guangdong and Zhejiang of China","authors":"Qiu Zhang , Mandong Huang , Xiaoxin Huang , Lu Gan , Yiling Li , Huiying Huang","doi":"10.1016/j.jhip.2025.03.004","DOIUrl":"10.1016/j.jhip.2025.03.004","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to analyze factors affecting the competitiveness of China's biopharmaceutical industry cluster, offering insights for policymakers and stakeholders, while providing Chinese experience and theoretical support for sustainable development of global biopharmaceutical industry clusters.</div></div><div><h3>Methods</h3><div>Based on relevant data from Guangdong and Zhejiang Provinces in China, the entropy value method was used to evaluate the comprehensive competitiveness of biopharmaceutical industry clusters in Guangdong and Zhejiang provinces respectively, and the principal component regression method was applied to respectively examine factors affecting the competitiveness of biopharmaceutical industry clusters in Guangdong and Zhejiang provinces.</div></div><div><h3>Results</h3><div>The competitiveness study showed that the comprehensive competitiveness scores of biopharmaceutical industry clusters in Guangdong and Zhejiang both show an upward trend from 2010 to 2020. From 2010 to 2020, the average value of Zhejiang's competitiveness was 0.53 and Guangdong's was 0.41. The influencing factor study showed that the top five factors affecting the competitiveness of biopharmaceutical industry clusters in Guangdong and Zhejiang were the same, namely, the ratio of general public service expenditure to regional GDP, ratio of regional road freight turnover to regional road mileage, proportion of R&D expenditure to total industrial output, ratio of total healthcare expenditure to provincial consumption, and product sales rate.</div></div><div><h3>Conclusion</h3><div>The results suggested that core factors affecting the competitiveness of China's biopharmaceutical industry cluster center on four aspects: infrastructure, innovation resources, enterprise performance, and market environment. Therefore, the primary strategy is to strengthen infrastructure construction and investment in innovation resources, while balancing enterprise performance with market environment optimization. This study pioneered the research on factors influencing the competitiveness of China's biopharmaceutical industry cluster, providing a new perspective and reference framework for subsequent research in this field.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"6 1","pages":"Pages 117-123"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preparation of TPM–NCs–gel and its effect on subcutaneous abscess caused by Staphylococcus aureus tpm - ncs凝胶的制备及其对金黄色葡萄球菌所致皮下脓肿的治疗作用

Journal of Holistic Integrative Pharmacy

Pub Date : 2025-03-01 DOI: 10.1016/j.jhip.2025.02.004

Quanwei Xie , Feirong Zhou , Runan He , Lianbao Ye , Zonghao Lin , Xiangyu Nie , Yuanzheng Wei , Chuqin Yu

Objective

The insoluble compound 1,1′-(2,4,6-trihydroxy-1,3-phenylene)bis(3-methylbutan-1-one) (TPM) is used in preparing a TPM nanocrystals gel (TPM–NCs–gel), and its in vitro antibacterial activity and therapeutic effect on subcutaneous abscesses caused by Staphylococcus aureus were evaluated.

Methods

The effect of a prescription technology on the particle size of a TPM–NCs suspension was investigated using a single factor, and the TPM–NCs prescription was optimized using a Box–Behnken design. A TPM–NCs–gel was prepared using hydroxyethyl cellulose–HHX (HEC–HHX) as a gel matrix and characterized. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of TPM–NCs–gel were determined with the microdilution method. The susceptibility of Staphylococcus aureus to mupirocin ointment, TPM–NCs–gel, and TPM–gel was evaluated by the disk diffusion method. The efficacy of the TPM–NCs–gel for subcutaneous abscess caused by Staphylococcus aureus was evaluated using a mouse model.

Results

The optimized TPM–NCs prescription consisted of Tween 80 and TPGS (2.47%), TPM (1.24%) and mannitol (2.32%). The size of the TPM–NCs was 98.2 ± 3.9 nm, and the polydispersion coefficient (PDI) was 0.235 ± 0.023. The particle size and PDI of the TPM–NCs–gel were 112.4 ± 7.3 nm and 0.148 ± 0.068, respectively. The MIC and MBC were both 2.98 μg/mL. After 12 days of administration, the bacteria in the abscess site of 2% TPM–NCs–gel experimental group were cleared, the inflammatory cells were reduced, and the skin structure was remodeled.

Conclusion

After TPM was prepared into TPM–NCs–gel, the antibacterial activity was enhanced, Staphylococcus aureus at the site of abscess was effectively removed, and wound healing was promoted.

目的用不溶性化合物1,1′-（2,4,6-三羟基-1,3-苯基）双（3-甲基丁烷-1- 1）（TPM）制备TPM纳米晶凝胶（TPM - ncs -凝胶），并评价其体外抗菌活性和对金黄色葡萄球菌皮下脓肿的治疗效果。方法采用单因素法考察处方工艺对TPM-NCs混悬液粒径的影响，采用Box-Behnken设计优化TPM-NCs的处方。以羟乙基纤维素- hhx （HEC-HHX）为凝胶基质制备了tpm - ncs -凝胶，并对其进行了表征。采用微量稀释法测定了tpm - ncs -凝胶的最小抑菌浓度（MIC）和最小杀菌浓度（MBC）。采用纸片扩散法评价金黄色葡萄球菌对莫匹罗星软膏、tpm - ncs -凝胶和tpm -凝胶的敏感性。采用小鼠模型评价tpm - ncs -凝胶治疗金黄色葡萄球菌皮下脓肿的疗效。结果优选的Tween 80 + TPGS（2.47%）、TPM(1.24%) +甘露醇（2.32%）。tpm - nc的尺寸为98.2±3.9 nm， PDI为0.235±0.023。tpm - ncs -凝胶的粒径为112.4±7.3 nm， PDI为0.148±0.068。MIC和MBC均为2.98 μg/mL。给药12 d后，2% tpm - ncs凝胶试验组脓肿部位细菌清除，炎症细胞减少，皮肤结构重塑。结论将TPM制备成TPM - ncs -凝胶后，抗菌活性增强，脓肿部位金黄色葡萄球菌被有效清除，促进伤口愈合。

{"title":"Preparation of TPM–NCs–gel and its effect on subcutaneous abscess caused by Staphylococcus aureus","authors":"Quanwei Xie , Feirong Zhou , Runan He , Lianbao Ye , Zonghao Lin , Xiangyu Nie , Yuanzheng Wei , Chuqin Yu","doi":"10.1016/j.jhip.2025.02.004","DOIUrl":"10.1016/j.jhip.2025.02.004","url":null,"abstract":"<div><h3>Objective</h3><div>The insoluble compound 1,1′-(2,4,6-trihydroxy-1,3-phenylene)bis(3-methylbutan-1-one) (TPM) is used in preparing a TPM nanocrystals gel (TPM–NCs–gel), and its <em>in vitro</em> antibacterial activity and therapeutic effect on subcutaneous abscesses caused by <em>Staphylococcus aureus</em> were evaluated.</div></div><div><h3>Methods</h3><div>The effect of a prescription technology on the particle size of a TPM–NCs suspension was investigated using a single factor, and the TPM–NCs prescription was optimized using a Box–Behnken design. A TPM–NCs–gel was prepared using hydroxyethyl cellulose–HHX (HEC–HHX) as a gel matrix and characterized. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of TPM–NCs–gel were determined with the microdilution method. The susceptibility of <em>Staphylococcus aureus</em> to mupirocin ointment, TPM–NCs–gel, and TPM–gel was evaluated by the disk diffusion method. The efficacy of the TPM–NCs–gel for subcutaneous abscess caused by <em>Staphylococcus aureus</em> was evaluated using a mouse model.</div></div><div><h3>Results</h3><div>The optimized TPM–NCs prescription consisted of Tween 80 and TPGS (2.47%), TPM (1.24%) and mannitol (2.32%). The size of the TPM–NCs was 98.2 ± 3.9 nm, and the polydispersion coefficient (PDI) was 0.235 ± 0.023. The particle size and PDI of the TPM–NCs–gel were 112.4 ± 7.3 nm and 0.148 ± 0.068, respectively. The MIC and MBC were both 2.98 μg/mL. After 12 days of administration, the bacteria in the abscess site of 2% TPM–NCs–gel experimental group were cleared, the inflammatory cells were reduced, and the skin structure was remodeled.</div></div><div><h3>Conclusion</h3><div>After TPM was prepared into TPM–NCs–gel, the antibacterial activity was enhanced, <em>Staphylococcus aureus</em> at the site of abscess was effectively removed, and wound healing was promoted.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"6 1","pages":"Pages 41-49"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Formulation and evaluation of carbamazepine loaded ethosomal nasal in-situ gel for brain targeted drug delivery 卡马西平运载体鼻腔原位凝胶脑靶向给药的研制与评价

Journal of Holistic Integrative Pharmacy

Pub Date : 2025-03-01 DOI: 10.1016/j.jhip.2025.03.002

Arjun Bilapatte , Anjali More , Kranti Satpute , Shoaeb Mohammad Syed

Objective

This study aimed to develop a novel intranasal drug delivery system for carbamazepine, an antiepileptic drug, to enhance its therapeutic efficacy through targeted and sustained delivery. The goal was to evaluate the suitability of various polymers and excipients for formulating an effective and mucoadhesive nasal gel.

Methods

Ethosomes were prepared using the cold method and evaluated for particle size, zeta potential, entrapment efficiency, and drug release. Gels were formulated using poloxamer 407 and carbopol 934 and characterized for their physicochemical properties. The optimized ethosomal gel was further assessed for mucoadhesive properties and in vitro drug release. Nasal in-situ gels were also prepared using carbopol and HPMC k 100, and their spreadability and drug release profiles were compared.

Results

The optimized ethosomal batch (ET3) exhibited a particle size of 200.7 nm, a zeta potential of −54.8 mV, and a high drug entrapment efficiency of 93%. The in vitro drug release from ET3 was 88.64%. Among the nasal in-situ gels, the carbopol-based batches demonstrated better spreadability compared to HPMC k 100. The optimized in-situ gel batch (G2) showed a gelation temperature of 33.7 °C and an in vitro drug release of 94.05%.

Conclusion

The developed ethosomal gel and in-situ gel formulations demonstrated sustained drug release, enhanced mucoadhesion, and targeted delivery, making them promising alternatives for the treatment of epilepsy. This intranasal delivery system could improve patient compliance and therapeutic outcomes by providing a non-invasive and effective route for carbamazepine administration.

目的研究一种新型的抗癫痫药物卡马西平鼻腔给药系统，通过靶向和持续给药来提高其治疗效果。目的是评估各种聚合物和赋形剂的适用性，以配制有效的黏附鼻凝胶。方法采用冷法制备囊体，并对其粒径、zeta电位、包封效率和药物释放进行评价。用poloxam407和carbopol 934配制凝胶，并对其理化性质进行了表征。进一步评价了优化后的酶体凝胶的黏附性能和体外释药性能。同时制备了caropol和HPMC k100鼻腔原位凝胶，并比较了它们的涂敷性和药物释放特性。结果优化后的酶体批（ET3）粒径为200.7 nm， zeta电位为- 54.8 mV，包封效率高达93%。ET3体外释药率为88.64%。在鼻腔原位凝胶中，与HPMC k100相比，碳水化合物基批具有更好的涂抹性。优化后的原位凝胶批（G2）凝胶温度为33.7℃，体外释药率为94.05%。结论所研制的溶栓体凝胶和原位凝胶制剂具有药物缓释、黏附增强、靶向给药等特点，是治疗癫痫的理想选择。这种鼻内给药系统提供了一种非侵入性和有效的卡马西平给药途径，可以提高患者的依从性和治疗效果。

{"title":"Formulation and evaluation of carbamazepine loaded ethosomal nasal in-situ gel for brain targeted drug delivery","authors":"Arjun Bilapatte , Anjali More , Kranti Satpute , Shoaeb Mohammad Syed","doi":"10.1016/j.jhip.2025.03.002","DOIUrl":"10.1016/j.jhip.2025.03.002","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to develop a novel intranasal drug delivery system for carbamazepine, an antiepileptic drug, to enhance its therapeutic efficacy through targeted and sustained delivery. The goal was to evaluate the suitability of various polymers and excipients for formulating an effective and mucoadhesive nasal gel.</div></div><div><h3>Methods</h3><div>Ethosomes were prepared using the cold method and evaluated for particle size, zeta potential, entrapment efficiency, and drug release. Gels were formulated using poloxamer 407 and carbopol 934 and characterized for their physicochemical properties. The optimized ethosomal gel was further assessed for mucoadhesive properties and <em>in vitro</em> drug release. Nasal in-situ gels were also prepared using carbopol and HPMC k 100, and their spreadability and drug release profiles were compared.</div></div><div><h3>Results</h3><div>The optimized ethosomal batch (ET3) exhibited a particle size of 200.7 nm, a zeta potential of −54.8 mV, and a high drug entrapment efficiency of 93%. The <em>in vitro</em> drug release from ET3 was 88.64%. Among the nasal in-situ gels, the carbopol-based batches demonstrated better spreadability compared to HPMC k 100. The optimized in-situ gel batch (G2) showed a gelation temperature of 33.7 °C and an <em>in vitro</em> drug release of 94.05%.</div></div><div><h3>Conclusion</h3><div>The developed ethosomal gel and in-situ gel formulations demonstrated sustained drug release, enhanced mucoadhesion, and targeted delivery, making them promising alternatives for the treatment of epilepsy. This intranasal delivery system could improve patient compliance and therapeutic outcomes by providing a non-invasive and effective route for carbamazepine administration.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"6 1","pages":"Pages 57-63"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protective potential of Carduus marianus extract against p-dimethylaminoazobenzene (pDAB) induced hepatocarcinogenesis in mice through apoptosis induction and antioxidant pathway 对二甲氨基偶氮苯（pDAB）诱导小鼠肝癌细胞凋亡及抗氧化作用的研究

Journal of Holistic Integrative Pharmacy

Pub Date : 2025-03-01 DOI: 10.1016/j.jhip.2025.02.005

Saili Paul , Anisur Rahman Khuda-Bukhsh

Objective

In homeopathy, ethanolic extract of Carduus marianus (EECM), is used against various liver disorders including cancer. This investigation aims at evaluating hepatoprotective potential of EECM, if any, against p-dimethylaminoazobenzene (pDAB)-induced hepatocarcinogenesis in mouse models in vivo and elucidating its possible underlying mechanism(s).

Methods

Randomized sets of inbred mice were chronically fed with different food regimens for varying periods of time and divided accordingly, 6 mice in each group, into control (Normal I and Alcohol II) and treated groups (III-V); group I: fed Normal diet, group II: Normal diet + Alcohol, group III: pDAB + Phenobarbital (PB), group IV: pDAB + PB + Alcohol, group V: pDAB + PB + EECM. They were sacrificed at day 30, 60, 90 and 120. All routine protocols were deployed for cytogenetical, enzymatic, and histopathological studies. Expressions of B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xl), Bcl-2 associated X protein (Bax), Cysteine aspartic acid protease-3 (Caspase-3), and Matrix metalloproteinase 9 (MMP-9) were evaluated at day 90 and 120 only. The DPPH free-radical scavenging activity of EECM was estimated to determine the antioxidant properties.

Results

No mice of groups I and II developed tumors in liver at any fixation intervals while all mice of groups (III-IV) developed liver tumors at three fixation intervals. But in group V mice, 4 each of 6 mice at 90 and 120 days, did not show tumor nodules in their livers, signifying that feeding of EECM could combat carcinogenesis. EECM reduced genotoxic effects and favorably modulated expression of Caspase 3 and MMP-9 as compared to control.

Conclusion

The treatment of EECM clearly demonstrated protective action against pDAB induced hepatocarcinogenesis in mice for delaying tumor progression, decreasing total tumor load and genotoxic effects, and also evidenced by favourable modulations of the apoptotic signal proteins like Bcl2, Bcl-xl. Bax, Caspase 3 and other marker enzymes AST (Aspartate amino transferase), ALT (Alanine amino transferase) etc. However, the molecular mechanism of this protective action still needs to be further elucidated.

目的利用顺势疗法，利用红桃醇提物（EECM）治疗包括癌症在内的多种肝脏疾病。本研究旨在评估EECM对pDAB（对二甲氨基偶氮苯）诱导的小鼠肝癌发生的肝保护潜力，并阐明其可能的潜在机制。方法随机选取一组自交系小鼠，按不同时间长期饲喂不同饮食方案，每组6只，分为对照组（正常I组和酒精II组）和治疗组（III-V组）；I组：正常饮食，II组：正常饮食+酒精，III组：pDAB +苯巴比妥（PB）， IV组：pDAB + PB +酒精，V组：pDAB + PB + EECM。分别于第30、60、90、120天处死。所有常规方案均用于细胞遗传学、酶学和组织病理学研究。b细胞淋巴瘤2 （Bcl-2）、超大型b细胞淋巴瘤（Bcl-xl）、Bcl-2相关X蛋白（Bax）、半胱氨酸天冬氨酸蛋白酶-3 （Caspase-3）和基质金属蛋白酶9 （MMP-9）的表达仅在第90天和120天进行评估。通过测定EECM对DPPH自由基的清除活性来确定其抗氧化性能。结果在任意固定时间内，ⅰ组和ⅱ组小鼠均未发生肝脏肿瘤，而ⅲ~ⅳ组小鼠在3个固定时间内均发生肝脏肿瘤。但在V组小鼠中，在90天和120天，每6只小鼠中有4只小鼠的肝脏未出现肿瘤结节，这表明喂食EECM可以对抗致癌作用。与对照组相比，EECM降低了基因毒性作用，有利地调节了Caspase 3和MMP-9的表达。结论EECM对pDAB诱导的小鼠肝癌具有明显的保护作用，可延缓肿瘤进展，降低肿瘤总负荷和基因毒性，并可调节凋亡信号蛋白如Bcl2、Bcl-xl。Bax、Caspase 3等标记酶AST（天冬氨酸氨基转移酶）、ALT（丙氨酸氨基转移酶）等。然而，这种保护作用的分子机制仍需进一步阐明。

{"title":"Protective potential of Carduus marianus extract against p-dimethylaminoazobenzene (pDAB) induced hepatocarcinogenesis in mice through apoptosis induction and antioxidant pathway","authors":"Saili Paul , Anisur Rahman Khuda-Bukhsh","doi":"10.1016/j.jhip.2025.02.005","DOIUrl":"10.1016/j.jhip.2025.02.005","url":null,"abstract":"<div><h3>Objective</h3><div>In homeopathy, ethanolic extract of <em>Carduus marianus</em> (EECM)<em>,</em> is used against various liver disorders including cancer. This investigation aims at evaluating hepatoprotective potential of EECM, if any, against p-dimethylaminoazobenzene (pDAB)-induced hepatocarcinogenesis in mouse models <em>in vivo</em> and elucidating its possible underlying mechanism(s).</div></div><div><h3>Methods</h3><div>Randomized sets of inbred mice were chronically fed with different food regimens for varying periods of time and divided accordingly, 6 mice in each group, into control (Normal I and Alcohol II) and treated groups (III-V); group I: fed Normal diet, group II: Normal diet + Alcohol, group III: pDAB + Phenobarbital (PB), group IV: pDAB + PB + Alcohol, group V: pDAB + PB + EECM. They were sacrificed at day 30, 60, 90 and 120. All routine protocols were deployed for cytogenetical, enzymatic, and histopathological studies. Expressions of B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xl), Bcl-2 associated X protein (Bax), Cysteine aspartic acid protease-3 (Caspase-3), and Matrix metalloproteinase 9 (MMP-9) were evaluated at day 90 and 120 only. The DPPH free-radical scavenging activity of EECM was estimated to determine the antioxidant properties.</div></div><div><h3>Results</h3><div>No mice of groups I and II developed tumors in liver at any fixation intervals while all mice of groups (III-IV) developed liver tumors at three fixation intervals. But in group V mice, 4 each of 6 mice at 90 and 120 days, did not show tumor nodules in their livers, signifying that feeding of EECM could combat carcinogenesis. EECM reduced genotoxic effects and favorably modulated expression of Caspase 3 and MMP-9 as compared to control.</div></div><div><h3>Conclusion</h3><div>The treatment of EECM clearly demonstrated protective action against pDAB induced hepatocarcinogenesis in mice for delaying tumor progression, decreasing total tumor load and genotoxic effects, and also evidenced by favourable modulations of the apoptotic signal proteins like Bcl2, Bcl-xl. Bax, Caspase 3 and other marker enzymes AST (Aspartate amino transferase), ALT (Alanine amino transferase) etc. However, the molecular mechanism of this protective action still needs to be further elucidated.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"6 1","pages":"Pages 64-73"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral pH-triggered colon-specific ketoprofen loaded microspheres for the better management of early morning symptoms associated with rheumatoid arthritis. Part II: Pharmacokinetic and pharmacodynamic assessment in rats 口服ph触发结肠特异性酮洛芬微球用于更好地管理与类风湿性关节炎相关的清晨症状第二部分：大鼠药代动力学和药效学评价

Journal of Holistic Integrative Pharmacy

Pub Date : 2025-03-01 DOI: 10.1016/j.jhip.2025.03.001

Krishna Sanka , Prabhakar Reddy Veerareddy , Rajeswara Rao Pragada

Objective

To evaluate the effectiveness of oral pH-triggered colon-specific ketoprofen-loaded microspheres (C-SKLMs) in managing early morning symptoms of rheumatoid arthritis (RA) through pharmacokinetic and pharmacodynamic assessments.

Methods

Pharmacokinetic parameters, including T_max, C_max, and mean residence time (MRT), were analyzed in animals treated with C-SKLMs and compared with pure ketoprofen. Pharmacodynamic evaluations assessed the ability of C-SKLMs to address early morning RA symptoms effectively by aligning drug release with the body's circadian rhythm.

Results

The T_max for the C-SKLMs group (9.33 ± 1.63 h) was significantly prolonged compared to pure ketoprofen (2 h), indicating delayed drug release tailored to circadian needs. The C_max for C-SKLMs (5.94 ± 1.20 μg/mL) was lower than that of pure ketoprofen (12.4 ± 3.00 μg/mL), demonstrating a controlled-release profile. Additionally, the MRT for C-SKLMs (12.96 ± 1.42 h) was approximately 1.4 times longer than for pure ketoprofen (9.44 ± 0.69 h), emphasizing extended drug release. Pharmacodynamic evaluations supported the superior effectiveness of C-SKLMs in managing early morning RA symptoms compared to pure ketoprofen.

Conclusion

C-SKLMs demonstrated significant potential to improve the management of early morning symptoms associated with RA through controlled, extended, and circadian-tailored drug release, making them a promising therapeutic approach.

目的通过药代动力学和药效学评估口服ph触发结肠特异性酮洛芬微球（C-SKLMs）治疗类风湿性关节炎（RA）清晨症状的有效性。方法分析c - sklm治疗动物的药代动力学参数，包括Tmax、Cmax和平均停留时间（MRT），并与纯酮洛芬进行比较。药效学评估评估了c - sklm通过调整药物释放与人体昼夜节律的关系来有效解决清晨RA症状的能力。结果C-SKLMs组的Tmax（9.33±1.63 h）比纯酮洛芬组（2 h）明显延长，表明药物释放延迟符合昼夜需求。C-SKLMs的Cmax（5.94±1.20 μg/mL）低于纯酮洛芬的Cmax(12.4±3.00 μg/mL)，具有控释特性。此外，C-SKLMs的MRT（12.96±1.42 h）大约是纯酮洛芬（9.44±0.69 h）的1.4倍，强调了药物释放的延长。与纯酮洛芬相比，药效学评估支持c - sklm在治疗清晨RA症状方面的优越效果。结论c - sklms通过控制、延长和昼夜节律的药物释放，显示出改善RA相关清晨症状管理的显著潜力，使其成为一种有前景的治疗方法。

{"title":"Oral pH-triggered colon-specific ketoprofen loaded microspheres for the better management of early morning symptoms associated with rheumatoid arthritis. Part II: Pharmacokinetic and pharmacodynamic assessment in rats","authors":"Krishna Sanka , Prabhakar Reddy Veerareddy , Rajeswara Rao Pragada","doi":"10.1016/j.jhip.2025.03.001","DOIUrl":"10.1016/j.jhip.2025.03.001","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the effectiveness of oral pH-triggered colon-specific ketoprofen-loaded microspheres (C-SKLMs) in managing early morning symptoms of rheumatoid arthritis (RA) through pharmacokinetic and pharmacodynamic assessments.</div></div><div><h3>Methods</h3><div>Pharmacokinetic parameters, including T<sub>max</sub>, C<sub>max</sub>, and mean residence time (MRT), were analyzed in animals treated with C-SKLMs and compared with pure ketoprofen. Pharmacodynamic evaluations assessed the ability of C-SKLMs to address early morning RA symptoms effectively by aligning drug release with the body's circadian rhythm.</div></div><div><h3>Results</h3><div>The T<sub>max</sub> for the C-SKLMs group (9.33 ± 1.63 h) was significantly prolonged compared to pure ketoprofen (2 h), indicating delayed drug release tailored to circadian needs. The C<sub>max</sub> for C-SKLMs (5.94 ± 1.20 μg/mL) was lower than that of pure ketoprofen (12.4 ± 3.00 μg/mL), demonstrating a controlled-release profile. Additionally, the MRT for C-SKLMs (12.96 ± 1.42 h) was approximately 1.4 times longer than for pure ketoprofen (9.44 ± 0.69 h), emphasizing extended drug release. Pharmacodynamic evaluations supported the superior effectiveness of C-SKLMs in managing early morning RA symptoms compared to pure ketoprofen.</div></div><div><h3>Conclusion</h3><div>C-SKLMs demonstrated significant potential to improve the management of early morning symptoms associated with RA through controlled, extended, and circadian-tailored drug release, making them a promising therapeutic approach.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"6 1","pages":"Pages 83-90"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitochondrial function: A new direction for the targeted treatment of cardiovascular diseases with Chinese herbal medicine 线粒体功能：中药靶向治疗心血管疾病的新方向

Journal of Holistic Integrative Pharmacy

Pub Date : 2025-03-01 DOI: 10.1016/j.jhip.2025.03.003

Lin Yang , Liang Wang , Baofeng Yang , Yue Zhang

Mitochondria play a central role in cardiovascular diseases, primarily by providing cellular energy and facilitating various cardiac functions. Excessive fat accumulation, circadian rhythm disturbances, viral infections, and persistent inflammation can lead to myocarditis, fibrosis, and infarction, thereby exacerbating the progression of cardiovascular diseases. As essential organelles for energy production, mitochondria exhibit remarkable dynamic adaptability and can integrate diverse cellular signaling pathways, endowing myocardial cells with both bioenergetic and biosynthetic versatility. Consequently, targeting mitochondria for cardiovascular disease therapy has gained increasing attention and is applicable to various cardiovascular conditions. Numerous mitochondrial adaptive mechanisms, including dynamics, metabolic processes, and apoptosis regulation, have emerged as promising therapeutic targets. Nevertheless, contemporary investigations into mitochondrial biology have unveiled their intricate structural and functional characteristics, as well as their complex roles within cellular systems, which present obstacles to the clinical implementation of mitochondria-focused cardiovascular therapies. Recent studies have found that traditional Chinese medicine (TCM) possesses the potential to effectively address cardiovascular diseases while enhancing the structural integrity and functional capacity of mitochondria. This review aims to offer a comprehensive analysis of the modulatory effects of TCM on cardiac mitochondria and its therapeutic ramifications for cardiovascular conditions.

线粒体在心血管疾病中发挥核心作用，主要是通过提供细胞能量和促进各种心脏功能。过度脂肪积累、昼夜节律紊乱、病毒感染和持续炎症可导致心肌炎、纤维化和梗死，从而加剧心血管疾病的进展。线粒体作为能量产生的重要细胞器，具有显著的动态适应性，可以整合多种细胞信号通路，赋予心肌细胞生物能量和生物合成的多功能性。因此，靶向线粒体治疗心血管疾病已越来越受到关注，并适用于各种心血管疾病。许多线粒体适应机制，包括动力学、代谢过程和细胞凋亡调节，已经成为有希望的治疗靶点。然而，当代对线粒体生物学的研究已经揭示了它们复杂的结构和功能特征，以及它们在细胞系统中的复杂作用，这给以线粒体为重点的心血管治疗的临床实施带来了障碍。最近的研究发现，中药在提高线粒体结构完整性和功能能力的同时，具有有效治疗心血管疾病的潜力。本文旨在全面分析中药对心脏线粒体的调节作用及其对心血管疾病的治疗效果。

{"title":"Mitochondrial function: A new direction for the targeted treatment of cardiovascular diseases with Chinese herbal medicine","authors":"Lin Yang , Liang Wang , Baofeng Yang , Yue Zhang","doi":"10.1016/j.jhip.2025.03.003","DOIUrl":"10.1016/j.jhip.2025.03.003","url":null,"abstract":"<div><div>Mitochondria play a central role in cardiovascular diseases, primarily by providing cellular energy and facilitating various cardiac functions. Excessive fat accumulation, circadian rhythm disturbances, viral infections, and persistent inflammation can lead to myocarditis, fibrosis, and infarction, thereby exacerbating the progression of cardiovascular diseases. As essential organelles for energy production, mitochondria exhibit remarkable dynamic adaptability and can integrate diverse cellular signaling pathways, endowing myocardial cells with both bioenergetic and biosynthetic versatility. Consequently, targeting mitochondria for cardiovascular disease therapy has gained increasing attention and is applicable to various cardiovascular conditions. Numerous mitochondrial adaptive mechanisms, including dynamics, metabolic processes, and apoptosis regulation, have emerged as promising therapeutic targets. Nevertheless, contemporary investigations into mitochondrial biology have unveiled their intricate structural and functional characteristics, as well as their complex roles within cellular systems, which present obstacles to the clinical implementation of mitochondria-focused cardiovascular therapies. Recent studies have found that traditional Chinese medicine (TCM) possesses the potential to effectively address cardiovascular diseases while enhancing the structural integrity and functional capacity of mitochondria. This review aims to offer a comprehensive analysis of the modulatory effects of TCM on cardiac mitochondria and its therapeutic ramifications for cardiovascular conditions.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"6 1","pages":"Pages 91-104"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Kalanchoe crenata decoction and infusion improve insulin resistance and fasting glycemia of diabetic obese rats MACAPOS 2 白藜芦醇煎剂及输注对糖尿病肥胖大鼠胰岛素抵抗及空腹血糖的影响

Journal of Holistic Integrative Pharmacy

Pub Date : 2025-03-01 DOI: 10.1016/j.jhip.2025.02.006

Ngakou Mukam Joseph , Mvongo Clémence , Mfopa Adamou , Kamgang Tchawou Armel Georges , Nkoubat Tchoundjwen Sandrine , Fankem Gaëtan Olivier , Noubissi Paul Aimé , Fokam Tagne Michel Archange , Kamgang René , Essame Oyono Jean-Louis

Objective

Kalanchoe crenata is a medicinal plant traditionally used in diabetes management. Type 2 diabetes is a metabolic disorder characterized by abnormally high glycemia and insulin resistance. We investigated the effects of Kalanchoe crenata aqueous extracts on diabetic rats.

Methods

Six-week-old normal rats were fed a high-fat diet for 16 weeks. Then, selected obese rats intravenously received a unique dose of streptozotocin (22.5 mg/kg b.w.). One week later, the obtained diabetic rats received K. crenata decoction (DKc) or infusion (IKc) once daily, respectively, at 37.5, 75.0, or 150.0 mg/kg b.w., or Metformin(70 mg/kg) once daily for 42 days, during which the fasting glycemia, urine volume, and water intake were recorded. At the end of the treatment, animals were subjected to oral glucose tolerance and insulin tolerance tests. They were then sacrificed; serum and pancreas were collected for insulinemia evaluation and histological analysis, respectively.

Results

Obese diabetic animals had fasting glycemia > 200 mg/dL. The DKc, IKc, and Metformin reduced (P < 0.05) glycemia with the maximum effect (P < 0.01) in the 6th week and improved glucose tolerance and insulin resistance. The extracts decreased 24-h urine volume as well as water intake and reduced insulinemia (P < 0.01): IKc75 (−66.4%) and IKc150 (−59.3%). This result was associated with decreased results of Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). The extracts improved the size of Langerhans islets. Infusion improved diabetes parameters to a greater extent than decoction.

Conclusion

Kalanchoe crenata aqueous extracts improved glucose tolerance and insulin resistance in diabetic rats. This study contributed to justifying the empirical use of this plant for diabetes management.

目的：白菖蒲是治疗糖尿病的传统药用植物。2型糖尿病是一种以异常高血糖和胰岛素抵抗为特征的代谢紊乱。我们研究了白桦水提物对糖尿病大鼠的影响。方法6周龄正常大鼠饲喂高脂饲料16周。然后，选择肥胖大鼠静脉注射独特剂量的链脲佐菌素（22.5 mg/kg b.w.）。1周后，将获得的糖尿病大鼠分别以37.5、75.0、150.0 mg/kg体重每日1次的剂量给予牛皮姜煎剂（DKc）或输注（IKc），或二甲双胍（70mg /kg）每日1次，连续42 d，记录空腹血糖、尿量、摄水量。在治疗结束时，对动物进行口服葡萄糖耐量和胰岛素耐量试验。然后他们被献祭；分别采集血清和胰腺进行胰岛素血症评估和组织学分析。结果6只糖尿病动物均有空腹血糖；200 mg / dL。DKc、IKc和二甲双胍降低(P <；0.05)，效果最大(P <；0.01)，改善葡萄糖耐量和胰岛素抵抗。提取物可减少24小时尿量、饮水量和胰岛素血症(P <；0.01): IKc75（- 66.4%）和IKc150（- 59.3%）。这一结果与胰岛素抵抗稳态模型评估（HOMA-IR）结果下降有关。提取物可改善朗格汉斯胰岛的大小。输液对糖尿病各项指标的改善程度大于煎剂。结论绿凤尾莲水提物可改善糖尿病大鼠的葡萄糖耐量和胰岛素抵抗。该研究有助于证明这种植物用于糖尿病管理的经验性使用。

{"title":"Kalanchoe crenata decoction and infusion improve insulin resistance and fasting glycemia of diabetic obese rats MACAPOS 2","authors":"Ngakou Mukam Joseph , Mvongo Clémence , Mfopa Adamou , Kamgang Tchawou Armel Georges , Nkoubat Tchoundjwen Sandrine , Fankem Gaëtan Olivier , Noubissi Paul Aimé , Fokam Tagne Michel Archange , Kamgang René , Essame Oyono Jean-Louis","doi":"10.1016/j.jhip.2025.02.006","DOIUrl":"10.1016/j.jhip.2025.02.006","url":null,"abstract":"<div><h3>Objective</h3><div><em>Kalanchoe crenata</em> is a medicinal plant traditionally used in diabetes management. Type 2 diabetes is a metabolic disorder characterized by abnormally high glycemia and insulin resistance. We investigated the effects of <em>Kalanchoe crenata</em> aqueous extracts on diabetic rats.</div></div><div><h3>Methods</h3><div>Six-week-old normal rats were fed a high-fat diet for 16 weeks. Then, selected obese rats intravenously received a unique dose of streptozotocin (22.5 mg/kg b.w.). One week later, the obtained diabetic rats received <em>K. crenata</em> decoction (DKc) or infusion (IKc) once daily, respectively, at 37.5, 75.0, or 150.0 mg/kg b.w., or Metformin(70 mg/kg) once daily for 42 days, during which the fasting glycemia, urine volume, and water intake were recorded. At the end of the treatment, animals were subjected to oral glucose tolerance and insulin tolerance tests. They were then sacrificed; serum and pancreas were collected for insulinemia evaluation and histological analysis, respectively.</div></div><div><h3>Results</h3><div>Obese diabetic animals had fasting glycemia > 200 mg/dL. The DKc, IKc, and Metformin reduced (<em>P</em> < 0.05) glycemia with the maximum effect (<em>P</em> < 0.01) in the 6th week and improved glucose tolerance and insulin resistance. The extracts decreased 24-h urine volume as well as water intake and reduced insulinemia (<em>P</em> < 0.01): IKc75 (−66.4%) and IKc150 (−59.3%). This result was associated with decreased results of Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). The extracts improved the size of Langerhans islets. Infusion improved diabetes parameters to a greater extent than decoction.</div></div><div><h3>Conclusion</h3><div><em>Kalanchoe crenata</em> aqueous extracts improved glucose tolerance and insulin resistance in diabetic rats. This study contributed to justifying the empirical use of this plant for diabetes management.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"6 1","pages":"Pages 50-56"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unravelling the gut-liver axis: The role of gut microbiota-mitochondria interactions in the pathogenesis and management of metabolic-associated fatty liver disease (MAFLD) 解开肠-肝轴：肠道微生物-线粒体相互作用在代谢相关脂肪肝（MAFLD）发病和管理中的作用

Journal of Holistic Integrative Pharmacy

Pub Date : 2025-03-01 DOI: 10.1016/j.jhip.2025.02.001

Binzhi Zhang , Xia Luo , Song Lei , Wenbo Gao , Zhipeng Chen , Qing Zhu , Lizheng Huang , Qinqiang Long

Metabolic-associated fatty liver disease (MAFLD) has emerged as a prevalent chronic liver disease. Our review of the existing literature reveals that the interplay between gut microbiota, mitochondria, and the liver is a key mechanism in the development of MAFLD. This paper distills the pathogenic role of gut microbiota in MAFLD through its influence on mitochondria and outlines the therapeutic mitochondrial mechanisms of MAFLD that leverage gut microbiota. It also touches on the traditional Chinese medicine perspective on the liver-intestine connection and the concept of ''qi'' in relation to mitochondria, as well as its modern medical counterpart. We conclude that the gut microbiota and their metabolites can directly or indirectly affect the intestinal mitochondria, leading to structural and functional changes. These changes include shifts in mitochondrial membrane potential, changes in permeability, and dysregulation of signaling pathways. As a result, the permeability of intestinal epithelial cells may be increased, and the integrity of the intestinal barrier may be compromised. The gut microbiota and their metabolites can then influence hepatic mitochondria through the hepatic-intestinal axis, triggering liver pathology. When liver damage occurs, their metabolites can enter the intestine and affect intestinal mitochondria and microbiota, which in turn can lead to a disrupted intestinal barrier and microbiota and a dysregulated homeostatic balance. Our extensive literature review suggests that the gut microbiota may mediate the treatment of MAFLD through mitochondrial pathways. The therapeutic approach of modulating the gut microbiota to regulate mitochondrial function and restore liver health is promising. Traditional Chinese medicine diets are particularly well suited for this strategy. Further research is warranted to fully elucidate the underlying mechanisms. By protecting the body's own mitochondrial function through the gut microbiota, we can effectively combat liver injury, providing a novel therapeutic avenue for the treatment of liver disease.

代谢性脂肪性肝病（MAFLD）已成为一种常见的慢性肝病。我们对现有文献的回顾表明，肠道微生物群，线粒体和肝脏之间的相互作用是MAFLD发展的关键机制。本文通过对线粒体的影响，提炼出肠道微生物群在MAFLD中的致病作用，并概述了利用肠道微生物群治疗MAFLD的线粒体机制。它还涉及了中医对肝肠联系的看法，以及与线粒体有关的“气”概念，以及与之相对应的现代医学。我们认为，肠道菌群及其代谢物可以直接或间接影响肠道线粒体，导致结构和功能的改变。这些变化包括线粒体膜电位的改变、通透性的改变和信号通路的失调。因此，肠上皮细胞的通透性可能增加，肠屏障的完整性可能受到损害。肠道菌群及其代谢物可通过肝肠轴影响肝线粒体，引发肝脏病理。当肝损伤发生时，其代谢物可进入肠道，影响肠道线粒体和微生物群，进而导致肠道屏障和微生物群被破坏，体内平衡失调。我们广泛的文献综述表明，肠道微生物群可能通过线粒体途径介导MAFLD的治疗。通过调节肠道微生物群来调节线粒体功能和恢复肝脏健康的治疗方法是有希望的。传统中医饮食特别适合这种策略。有必要进一步研究以充分阐明其潜在机制。通过肠道菌群保护人体自身的线粒体功能，我们可以有效地对抗肝损伤，为肝脏疾病的治疗提供新的治疗途径。

{"title":"Unravelling the gut-liver axis: The role of gut microbiota-mitochondria interactions in the pathogenesis and management of metabolic-associated fatty liver disease (MAFLD)","authors":"Binzhi Zhang , Xia Luo , Song Lei , Wenbo Gao , Zhipeng Chen , Qing Zhu , Lizheng Huang , Qinqiang Long","doi":"10.1016/j.jhip.2025.02.001","DOIUrl":"10.1016/j.jhip.2025.02.001","url":null,"abstract":"<div><div>Metabolic-associated fatty liver disease (MAFLD) has emerged as a prevalent chronic liver disease. Our review of the existing literature reveals that the interplay between gut microbiota, mitochondria, and the liver is a key mechanism in the development of MAFLD. This paper distills the pathogenic role of gut microbiota in MAFLD through its influence on mitochondria and outlines the therapeutic mitochondrial mechanisms of MAFLD that leverage gut microbiota. It also touches on the traditional Chinese medicine perspective on the liver-intestine connection and the concept of ''<em>qi</em>'' in relation to mitochondria, as well as its modern medical counterpart. We conclude that the gut microbiota and their metabolites can directly or indirectly affect the intestinal mitochondria, leading to structural and functional changes. These changes include shifts in mitochondrial membrane potential, changes in permeability, and dysregulation of signaling pathways. As a result, the permeability of intestinal epithelial cells may be increased, and the integrity of the intestinal barrier may be compromised. The gut microbiota and their metabolites can then influence hepatic mitochondria through the hepatic-intestinal axis, triggering liver pathology. When liver damage occurs, their metabolites can enter the intestine and affect intestinal mitochondria and microbiota, which in turn can lead to a disrupted intestinal barrier and microbiota and a dysregulated homeostatic balance. Our extensive literature review suggests that the gut microbiota may mediate the treatment of MAFLD through mitochondrial pathways. The therapeutic approach of modulating the gut microbiota to regulate mitochondrial function and restore liver health is promising. Traditional Chinese medicine diets are particularly well suited for this strategy. Further research is warranted to fully elucidate the underlying mechanisms. By protecting the body's own mitochondrial function through the gut microbiota, we can effectively combat liver injury, providing a novel therapeutic avenue for the treatment of liver disease.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"6 1","pages":"Pages 23-40"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anticancer flavonoids producing endophytic fungi: A review 抗癌类黄酮内生真菌研究进展

Journal of Holistic Integrative Pharmacy

Pub Date : 2024-12-01 DOI: 10.1016/j.jhip.2024.11.002

Kirti G. Sahu , Deepak S. Khobragade , Shriniwas P. Patil

Plants living in different environments inhabit endophytic microbes. The relationship between plants and endophytic microbes may be symbiotic or parasitic. Transmission of endophytes varies when they are obtained through roots or cracks on bark or airborne spores from soil or originated from seeds or pollens. Endophytes could be bacteria or fungi. So far, actual flavonoids have been detected from endophytic fungi only. Several flavonoids like rutin, quercetin, kaempferol, naringenin, vitexin, apigenin, luteolin, chrysin, and silymarin are isolated from endophytic fungi. These flavonoids are tested for their anticancer activity on different cell lines and their mechanisms were determined. This review focuses on endophytic fungi from which anticancer flavonoids have been reported.

生长在不同环境中的植物都栖息着内生微生物。植物与内生微生物的关系可能是共生的，也可能是寄生的。内生菌的传播方式各不相同，有的是通过树根或树皮上的裂缝，有的是通过空气传播的土壤孢子，有的是来自种子或花粉。内生菌可以是细菌或真菌。到目前为止，真正的黄酮类化合物只从内生真菌中检测到。从内生真菌中分离出芦丁、槲皮素、山奈酚、柚皮素、牡荆素、芹菜素、木犀草素、金菊素、水飞蓟素等黄酮类化合物。对这些类黄酮在不同细胞系上的抗癌活性进行了测试，并确定了其作用机制。本文就近年来报道的从内生真菌中提取抗肿瘤类黄酮的研究进展进行综述。

引用次数: 0

Visual analysis of drug research and development based on artificial intelligence 基于人工智能的药物研发可视化分析

Journal of Holistic Integrative Pharmacy

Pub Date : 2024-12-01 DOI: 10.1016/j.jhip.2024.12.002

Wei Wei , Chao Song , Changxing Qi , Xin Zhang , Xiaoyi Zhang , Run Pu , Yi Ao

The iteration of artificial intelligence (AI) technology provides new opportunities for drug research and experimental development. In recent years, AI-based drug research has continuously made new progress and has garnered widespread attention. This study retrieved data from a total of 23,096 papers in AI-based drug research and development from the Web of Science up to May 14, 2024, and conducted bibliometric analysis using VOSviewer software. The results indicated that the AI-based drug research and development is a globally recognized hotspot, and the United States holds a certain authority in this field, while China ranks second in total publication output. The integration of AI technology with drug development primarily involves four stages: drug discovery, preclinical research, clinical trials, and drug manufacturing. So, AI technology has been applied throughout the entire process of drug development. AI-based virtual drug screening and structure-activity relationship analysis started early, while graph neural networks, pre-trained models (Transformer), interpretable AI technology, ChatGPT, and large language models were significantly highlighted in the last 3 years. Moreover, since 2020, AI-based drug repurposing, molecular dynamics simulation, 3D printing, and drug delivery system design have emerged as research hotspots and have been mainly applied to, particularly, on COVID-19, disease prognosis, liver cancer, lung cancer, and immunotherapy.

人工智能（AI）技术的迭代为药物研究和实验开发提供了新的机遇。近年来，基于人工智能的药物研究不断取得新进展，受到广泛关注。本研究从Web of Science截至2024年5月14日的23,096篇基于人工智能的药物研发论文中检索数据，使用VOSviewer软件进行文献计量学分析。结果表明，基于人工智能的药物研发是全球公认的热点，美国在该领域拥有一定的权威，而中国在该领域的总发表量排名第二。人工智能技术与药物开发的整合主要涉及四个阶段：药物发现、临床前研究、临床试验和药物生产。因此，人工智能技术已经应用于药物开发的整个过程。基于人工智能的虚拟药物筛选和构效关系分析起步较早，而图神经网络、预训练模型（Transformer）、可解释性人工智能技术、ChatGPT和大型语言模型在最近3年得到了显著的突出。此外，自2020年以来，基于人工智能的药物再利用、分子动力学模拟、3D打印、给药系统设计等成为研究热点，主要应用于COVID-19、疾病预后、肝癌、肺癌、免疫治疗等领域。

{"title":"Visual analysis of drug research and development based on artificial intelligence","authors":"Wei Wei , Chao Song , Changxing Qi , Xin Zhang , Xiaoyi Zhang , Run Pu , Yi Ao","doi":"10.1016/j.jhip.2024.12.002","DOIUrl":"10.1016/j.jhip.2024.12.002","url":null,"abstract":"<div><div>The iteration of artificial intelligence (AI) technology provides new opportunities for drug research and experimental development. In recent years, AI-based drug research has continuously made new progress and has garnered widespread attention. This study retrieved data from a total of 23,096 papers in AI-based drug research and development from the Web of Science up to May 14, 2024, and conducted bibliometric analysis using VOSviewer software. The results indicated that the AI-based drug research and development is a globally recognized hotspot, and the United States holds a certain authority in this field, while China ranks second in total publication output. The integration of AI technology with drug development primarily involves four stages: drug discovery, preclinical research, clinical trials, and drug manufacturing. So, AI technology has been applied throughout the entire process of drug development. AI-based virtual drug screening and structure-activity relationship analysis started early, while graph neural networks, pre-trained models (Transformer), interpretable AI technology, ChatGPT, and large language models were significantly highlighted in the last 3 years. Moreover, since 2020, AI-based drug repurposing, molecular dynamics simulation, 3D printing, and drug delivery system design have emerged as research hotspots and have been mainly applied to, particularly, on COVID-19, disease prognosis, liver cancer, lung cancer, and immunotherapy.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"5 4","pages":"Pages 323-332"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0